News | April 26, 2024
Divi's Laboratories to expand capacity at an outlay of approx. Rs. 700 Cr
The proposed facility is expected to be operational around January, 2027
The proposed facility is expected to be operational around January, 2027
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
Breakthrough Therapy designation for pain associated with DPN granted by FDA
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
Around 7% of the Indian population suffers from IBS
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
A significant proportion of healthcare professionals still tend to favor branded drugs
Subscribe To Our Newsletter & Stay Updated
